Bicara Therapeutics’ (NASDAQ:BCAX – Get Free Report) lock-up period is set to expire on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. After the expiration of Bicara Therapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on BCAX shares. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a report on Wednesday, February 12th. HC Wainwright raised their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $41.20.
Read Our Latest Research Report on BCAX
Bicara Therapeutics Price Performance
Institutional Trading of Bicara Therapeutics
Several large investors have recently bought and sold shares of BCAX. Vestal Point Capital LP boosted its stake in shares of Bicara Therapeutics by 67.1% during the fourth quarter. Vestal Point Capital LP now owns 710,000 shares of the company’s stock valued at $12,368,000 after purchasing an additional 285,000 shares in the last quarter. Wexford Capital LP purchased a new position in shares of Bicara Therapeutics during the fourth quarter valued at approximately $348,000. Red Tree Management LLC purchased a new position in Bicara Therapeutics in the fourth quarter worth $55,230,000. Nuveen Asset Management LLC purchased a new position in Bicara Therapeutics in the fourth quarter worth $436,000. Finally, Orbimed Advisors LLC raised its stake in shares of Bicara Therapeutics by 9.7% in the fourth quarter. Orbimed Advisors LLC now owns 298,301 shares of the company’s stock valued at $5,196,000 after buying an additional 26,391 shares during the period.
Bicara Therapeutics Company Profile
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Recommended Stories
- Five stocks we like better than Bicara Therapeutics
- How to invest in marijuana stocks in 7 steps
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Investing In Automotive Stocks
- 3 Stocks to Buy While Others Stay on the Sidelines
- Why Are Stock Sectors Important to Successful Investing?
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.